Zomedica Announces Issuance of Additional Patent for its TRUVIEW(R) Microscope
Zomedica (OTCQB:ZOMDF) has been granted a new U.S. Patent (No. 12,299,917 B2) for its TRUVIEW microscope, specifically covering Methods and Systems for Slide Imaging Calibration. The patent strengthens the company's intellectual property portfolio, which now comprises 77 U.S. patents, 144 international patents, 33 U.S. trademarks, and 107 foreign trademarks.
Bill Campbell, VP of Imaging Systems and TRUVIEW's inventor, emphasized the patent's significance in validating their focusing system innovation. CEO Larry Heaton highlighted how this protection enables continued investment in market expansion while maintaining product uniqueness.
Zomedica (OTCQB:ZOMDF) ha ottenuto un nuovo brevetto statunitense (n. 12.299.917 B2) per il suo microscopio TRUVIEW, che riguarda specificamente i Metodi e Sistemi per la Calibrazione dell'Imaging su Vetrini. Questo brevetto rafforza il portafoglio di proprietà intellettuale dell'azienda, che ora include 77 brevetti statunitensi, 144 brevetti internazionali, 33 marchi statunitensi e 107 marchi esteri.
Bill Campbell, vicepresidente dei Sistemi di Imaging e inventore del TRUVIEW, ha sottolineato l'importanza del brevetto nel convalidare l'innovazione del loro sistema di messa a fuoco. Il CEO Larry Heaton ha evidenziato come questa protezione consenta di continuare a investire nell'espansione del mercato, mantenendo al contempo l'unicità del prodotto.
Zomedica (OTCQB:ZOMDF) ha recibido una nueva patente estadounidense (No. 12,299,917 B2) para su microscopio TRUVIEW, que cubre específicamente Métodos y Sistemas para la Calibración de Imágenes en Portaobjetos. La patente fortalece la cartera de propiedad intelectual de la empresa, que ahora incluye 77 patentes estadounidenses, 144 patentes internacionales, 33 marcas registradas en EE.UU. y 107 marcas registradas en el extranjero.
Bill Campbell, vicepresidente de Sistemas de Imagen e inventor del TRUVIEW, destacó la importancia de la patente para validar la innovación de su sistema de enfoque. El CEO Larry Heaton resaltó cómo esta protección permite continuar invirtiendo en la expansión del mercado mientras se mantiene la singularidad del producto.
Zomedica (OTCQB:ZOMDF)는 자사의 TRUVIEW 현미경에 대해 미국 특허 번호 12,299,917 B2를 새로 취득했습니다. 이 특허는 슬라이드 이미지 보정 방법 및 시스템을 구체적으로 다루고 있습니다. 이번 특허로 회사의 지적 재산권 포트폴리오는 미국 특허 77건, 국제 특허 144건, 미국 상표 33건, 해외 상표 107건을 포함하게 되었습니다.
영상 시스템 부사장이자 TRUVIEW 발명가인 Bill Campbell은 이 특허가 그들의 초점 맞추기 시스템 혁신을 입증하는 데 중요한 의미가 있다고 강조했습니다. CEO Larry Heaton은 이 보호 조치가 제품의 독창성을 유지하면서 시장 확장에 지속적으로 투자할 수 있게 해준다고 밝혔습니다.
Zomedica (OTCQB:ZOMDF) s'est vu accorder un nouveau brevet américain (n° 12,299,917 B2) pour son microscope TRUVIEW, couvrant spécifiquement les Méthodes et Systèmes de Calibration d'Imagerie sur Lames. Ce brevet renforce le portefeuille de propriété intellectuelle de l'entreprise, qui comprend désormais 77 brevets américains, 144 brevets internationaux, 33 marques américaines et 107 marques étrangères.
Bill Campbell, vice-président des systèmes d'imagerie et inventeur du TRUVIEW, a souligné l'importance de ce brevet pour valider l'innovation de leur système de mise au point. Le PDG Larry Heaton a mis en avant comment cette protection permet de continuer à investir dans l'expansion du marché tout en préservant l'unicité du produit.
Zomedica (OTCQB:ZOMDF) hat ein neues US-Patent (Nr. 12.299.917 B2) für sein TRUVIEW-Mikroskop erhalten, das speziell Methoden und Systeme zur Kalibrierung von Objektträgerbildern abdeckt. Das Patent stärkt das geistige Eigentumsportfolio des Unternehmens, das nun 77 US-Patente, 144 internationale Patente, 33 US-Marken und 107 ausländische Marken umfasst.
Bill Campbell, Vizepräsident für Bildgebungssysteme und Erfinder des TRUVIEW, betonte die Bedeutung des Patents für die Validierung ihrer Fokussierungssystem-Innovation. CEO Larry Heaton hob hervor, wie dieser Schutz fortgesetzte Investitionen in die Markterweiterung ermöglicht und gleichzeitig die Einzigartigkeit des Produkts bewahrt.
- Expansion of intellectual property portfolio with new strategic patent
- Strong IP protection with 221 total patents and 140 trademarks globally
- Protection of proprietary technology enables market expansion investment
- None.
Insights
Zomedica strengthens competitive position with new TRUVIEW microscope patent, bolstering its extensive 221-patent portfolio in veterinary diagnostics.
Zomedica's newly secured patent (US No. 12,299,917 B2) for the TRUVIEW microscope's slide imaging calibration represents a strategic strengthening of their market position in veterinary diagnostics. This patent specifically protects their focusing system technology, which is critical for maintaining competitive differentiation in digital microscopy for veterinary applications.
The patent issuance is particularly significant when viewed within the context of Zomedica's broader intellectual property strategy. With this addition, their portfolio now encompasses 77 US patents and 144 international patents, alongside 33 US trademarks and 107 foreign trademarks. This extensive IP protection creates substantial barriers to entry for potential competitors in the veterinary point-of-care diagnostics space.
The comments from Bill Campbell, VP of Imaging Systems and inventor of the TRUVIEW microscope, indicate that this patent specifically protects their focusing system technology. This suggests the technology delivers meaningful improvements in image quality and clinical usability - critical factors for adoption in veterinary practices where diagnostic accuracy and workflow efficiency directly impact business performance.
For investors, this patent reinforces Zomedica's long-term strategy of creating value through proprietary technology. By securing exclusive rights to their innovations, they position themselves to potentially command premium pricing and protect market share in the growing veterinary diagnostics segment. The continued expansion of their IP portfolio demonstrates ongoing R&D productivity and a commitment to maintaining technological leadership in this specialized field.
Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks
ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current intellectual property portfolio.
The U.S. Patent related to the TRUVIEW microscope, manufactured, sold and distributed by Zomedica, was U.S. Patent No. 12,299,917 B2 issued recently for the Methods and Systems for Slide Imaging Calibration.
Bill Campbell, Zomedica's Vice President of Imaging Systems and inventor of the TRUVIEW microscope, stated, "Securing this patent is a significant milestone that underscores our commitment to innovation in digital microscopy. This protection not only validates the uniqueness of our focusing system but also strengthens our position as a leader in imaging solutions. We are excited about the possibilities this opens for enhancing image quality and usability in clinical applications.
With the addition of this recently issued patent, Zomedica's IP portfolio now includes 77 issued U.S. patents and 144 issued international patents as well as 33 registered U.S. trademarks and 107 registered foreign trademarks related to its therapeutic device and diagnostic products.
Larry Heaton, Chief Executive Officer of Zomedica stated, "We are pleased to add this patent protecting our innovative TRUVIEW device to our growing portfolio. The Zomedica Research & Development team has been actively expanding our intellectual property portfolio through ongoing development of our innovative products. This protection enables us to devote resources to investing in growing new markets for our unique products, knowing that Zomedica's highly differentiated proprietary products will remain unique."
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What is the new patent Zomedica (ZOMDF) received for its TRUVIEW microscope?
How many patents and trademarks does Zomedica currently own?
Who is the inventor of Zomedica's TRUVIEW microscope?
What are the potential benefits of Zomedica's new TRUVIEW microscope patent?
